Patents by Inventor Mark UHLIK

Mark UHLIK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BETA GLUCAN IMMUNOPHARMACODYNAMICS
    Publication number: 20240019444
    Abstract: This disclosure provides, in one aspect, dosing strategies for soluble ?-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble ?-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-?-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.
    Type: Application
    Filed: September 19, 2023
    Publication date: January 18, 2024
    Inventors: Nandita Bose, Nadine Ottoson, Ben Harrison, Jamie Lowe, Mark Uhlik, Jeremy Graff, Richard Huhn
  • Beta glucan immunopharmacodynamics
    Patent number: 11815435
    Abstract: This disclosure provides, in one aspect, dosing strategies for soluble ?-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble ?-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-?-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: November 14, 2023
    Assignee: HiberCell, Inc.
    Inventors: Nandita Bose, Nadine Ottoson, Ben Harrison, Jamie Lowe, Mark Uhlik, Jeremy Graff, Richard Huhn
  • BETA GLUCAN IMMUNOPHARMACODYNAMICS
    Publication number: 20200033362
    Abstract: This disclosure provides, in one aspect, dosing strategies for soluble ?-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble ?-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-?-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.
    Type: Application
    Filed: February 23, 2018
    Publication date: January 30, 2020
    Applicant: BIOTHERA PHARMACEUTICALS, INC.
    Inventors: Nandita BOSE, Nadine OTTOSON, Ben HARRISON, Jamie LOWE, Mark UHLIK, Jeremy GRAFF, Richard HUHN